TriangleNCT01777152 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- Up to 90 months
What was measured
The time from randomization to death due to any cause.
Analysis population: The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients are included in the treatment group assigned at randomization regardless of the actual treatment received.
Groups in this outcome
A+CHP
brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
CHOP
cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
| Group | Source count |
|---|---|
| A+CHP | 226 |
| CHOP | 226 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| A+CHP | NA | Not reported | 0.0 | 86.5 | The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm. |
| CHOP | NA | Not reported | 0.1 | 90.0 | The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm. |
Complete source fields
- classes
- categories
- measurements
- comment
- The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm.
- group Id
- OG000
- lower Limit
- 0.0
- upper Limit
- 86.5
- value
- NA
- comment
- The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm.
- group Id
- OG001
- lower Limit
- 0.1
- upper Limit
- 90.0
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 226
- group Id
- OG001
- value
- 226
- units
- Participants
- description
- The time from randomization to death due to any cause.
- dispersion Type
- Full Range
- groups
- description
- brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
- id
- OG000
- title
- A+CHP
- description
- cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
- id
- OG001
- title
- CHOP
- param Type
- MEDIAN
- population Description
- The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients are included in the treatment group assigned at randomization regardless of the actual treatment received.
- reporting Status
- POSTED
- time Frame
- Up to 90 months
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice